Harpoon Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023062125 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.60M
YoY Change -52.19%
Cash & Equivalents $17.74M
Short-Term Investments $13.90M
Other Short-Term Assets $2.700M
YoY Change -11.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $34.30M
YoY Change -50.4%
LONG-TERM ASSETS
Property, Plant & Equipment $3.527M
YoY Change -55.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $898.0K
YoY Change 10.73%
Total Long-Term Assets $13.28M
YoY Change -7.42%
TOTAL ASSETS
Total Short-Term Assets $34.30M
Total Long-Term Assets $13.28M
Total Assets $47.58M
YoY Change -43.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.435M
YoY Change 30.11%
Accrued Expenses $11.70M
YoY Change -25.16%
Deferred Revenue $0.00
YoY Change -100.0%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.11M
YoY Change -66.51%
LONG-TERM LIABILITIES
Long-Term Debt $8.800M
YoY Change
Other Long-Term Liabilities $16.10M
YoY Change 28.56%
Total Long-Term Liabilities $24.90M
YoY Change 98.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.11M
Total Long-Term Liabilities $24.90M
Total Liabilities $43.04M
YoY Change -35.36%
SHAREHOLDERS EQUITY
Retained Earnings -$364.6M
YoY Change 9.13%
Common Stock $369.1M
YoY Change 5.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.541M
YoY Change
Total Liabilities & Shareholders Equity $47.58M
YoY Change -43.02%

Cashflow Statement

Concept 2023 Q4 2023 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001708493
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax
CY2022Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax
CY2023Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38800
dei Entity Registrant Name
EntityRegistrantName
Harpoon Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3458693
dei Entity Address Address Line1
EntityAddressAddressLine1
611 Gateway Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
443-7400
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
HARP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16932272
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17738000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51614000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
13870000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1498000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2688000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1615000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
34296000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
54727000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3527000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7237000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8857000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10854000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
898000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
911000
CY2023Q3 us-gaap Assets
Assets
47578000
CY2022Q4 us-gaap Assets
Assets
73729000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3435000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4712000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11697000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14361000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
30937000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2974000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2423000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
18106000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
52433000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2314000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11530000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13583000
CY2023Q3 harp Embedded Redemption Liability
EmbeddedRedemptionLiability
4574000
CY2022Q4 harp Embedded Redemption Liability
EmbeddedRedemptionLiability
0
CY2023Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount
SharesSubjectToMandatoryRedemptionSettlementTermsAmount
8827000
CY2022Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount
SharesSubjectToMandatoryRedemptionSettlementTermsAmount
0
CY2023Q3 us-gaap Liabilities
Liabilities
43037000
CY2022Q4 us-gaap Liabilities
Liabilities
68330000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4108769
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4108769
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3578668
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3578668
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
369141000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
357921000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-364602000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-352523000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4541000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
5399000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47578000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73729000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4448000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13617000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33252000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27826000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4448000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13617000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33252000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27826000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12325000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20977000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39684000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62446000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4262000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4529000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12250000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14993000
CY2023Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
1729000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
16587000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
25506000
us-gaap Operating Expenses
OperatingExpenses
53663000
us-gaap Operating Expenses
OperatingExpenses
77439000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12139000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11889000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20411000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49613000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
480000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
289000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1520000
us-gaap Investment Income Interest
InvestmentIncomeInterest
433000
CY2023Q3 us-gaap Interest Expense
InterestExpense
2046000
CY2022Q3 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
3744000
us-gaap Interest Expense
InterestExpense
0
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11903000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-40000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10556000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-132000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1802000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11640000
us-gaap Net Income Loss
NetIncomeLoss
-12079000
us-gaap Net Income Loss
NetIncomeLoss
-49312000
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-4000
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
28000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
4000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
19000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1806000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11612000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12075000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49293000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.52
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-14.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-14.95
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3947995
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3947995
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3306215
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3306215
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3807955
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3807955
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3299357
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3299357
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
5399000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
93000
CY2023Q1 harp Issuance Of Common Stock Warrants In Connection With Mandatorily Redeemable Preferred Stock
IssuanceOfCommonStockWarrantsInConnectionWithMandatorilyRedeemablePreferredStock
3881000
CY2023Q1 harp Issuance Of Common Stock Pursuant To Atm Facility
IssuanceOfCommonStockPursuantToAtmFacility
1525000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1133000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11338000
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
3000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
696000
CY2023Q2 harp Issuance Of Common Stock Pursuant To Atm Facility
IssuanceOfCommonStockPursuantToAtmFacility
171000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1065000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
1061000
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
5000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2998000
CY2023Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
10
CY2023Q3 harp Issuance Of Common Stock Pursuant To Atm Facility
IssuanceOfCommonStockPursuantToAtmFacility
2335000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
96000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
918000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1802000
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-4000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4541000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
58070000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
830000
CY2022Q1 harp Stock Issued During Period Value Vesting Of Early Exercisable Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisableStockOptions
3000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2843000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20321000
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-41000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
41384000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
53000
CY2022Q2 harp Stock Issued During Period Value Vesting Of Early Exercisable Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisableStockOptions
3000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2521000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17351000
CY2022Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
32000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
26642000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
101000
CY2022Q3 harp Stock Issued During Period Value Vesting Of Early Exercisable Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisableStockOptions
2000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1779000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11640000
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
28000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
16912000
us-gaap Profit Loss
ProfitLoss
-12079000
us-gaap Profit Loss
ProfitLoss
-49312000
us-gaap Share Based Compensation
ShareBasedCompensation
3116000
us-gaap Share Based Compensation
ShareBasedCompensation
7143000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1268000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1679000
harp Non Cash Lease Expense
NonCashLeaseExpense
1079000
harp Non Cash Lease Expense
NonCashLeaseExpense
508000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-443000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
1729000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
10971000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
harp Issuance Cost For Embedded Redemption Liability
IssuanceCostForEmbeddedRedemptionLiability
807000
harp Issuance Cost For Embedded Redemption Liability
IssuanceCostForEmbeddedRedemptionLiability
0
harp Accretion Of Redemption Value Discount
AccretionOfRedemptionValueDiscount
3744000
harp Accretion Of Redemption Value Discount
AccretionOfRedemptionValueDiscount
0
harp Net Amortization Of Discounts And Premiums On Marketable Securities
NetAmortizationOfDiscountsAndPremiumsOnMarketableSecurities
215000
harp Net Amortization Of Discounts And Premiums On Marketable Securities
NetAmortizationOfDiscountsAndPremiumsOnMarketableSecurities
-413000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1344000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
455000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-41000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-49000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1008000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-53000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2848000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1724000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-33251000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-27826000
harp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1502000
harp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1214000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50991000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70792000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
91000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
319000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
15652000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
24426000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3500000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
100235000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
1279000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10964000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
75490000
harp Proceeds From Issuance Of Series A Mandatorily Redeemable Preferred Stock
ProceedsFromIssuanceOfSeriesAMandatorilyRedeemablePreferredStock
23703000
harp Proceeds From Issuance Of Series A Mandatorily Redeemable Preferred Stock
ProceedsFromIssuanceOfSeriesAMandatorilyRedeemablePreferredStock
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
311000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4031000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
983000
harp Proceeds From Issuance Of Common Stock In Connection With Employee Benefit Plans
ProceedsFromIssuanceOfCommonStockInConnectionWithEmployeeBenefitPlans
189000
harp Proceeds From Issuance Of Common Stock In Connection With Employee Benefit Plans
ProceedsFromIssuanceOfCommonStockInConnectionWithEmployeeBenefitPlans
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27612000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
983000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-34343000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5681000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52287000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45360000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17944000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51041000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
28000
harp Reclassification Of Employee Stock Liability To Equity Upon Vesting
ReclassificationOfEmployeeStockLiabilityToEquityUponVesting
0
harp Reclassification Of Employee Stock Liability To Equity Upon Vesting
ReclassificationOfEmployeeStockLiabilityToEquityUponVesting
8000
harp Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2015-03
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-364600000
CY2023Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
31600000
CY2023Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 10
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51614000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
206000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:2.253%;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of unaudited condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying unaudited condensed financial statements include, but are not limited to, valuation of the Series A Preferred Stock, valuation of the derivative liabilities, allowance for credit losses, the fair value of stock options and warrants, the research period of the collaboration agreements with AbbVie Biotechnology Ltd. (“AbbVie”), operating lease asset and lease liabilities, income tax uncertainties and certain accruals.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
harp Highly Liquid Investments Purchased With Maximum Original Maturity Period
HighlyLiquidInvestmentsPurchasedWithMaximumOriginalMaturityPeriod
P3M
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
200000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
700000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17738000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
673000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17944000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52287000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:2.267%;text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company is subject to credit risk from its portfolio of cash equivalents and marketable securities. The Company invests in money market funds through a major U.S. bank and is exposed to credit risk in the event of default by the financial institution to the</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extent </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of amounts recorded on the unaudited condensed balance sheets. The Company invests in money market funds and investment grade short- to intermediate-term fixed income securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company’s investment policy, in order of priority, are as follows: preservation of principal, liquidity of investments, fiduciary control of cash and investments, prevention of inappropriate concentrations of investments, and obtaining the best yields. The Company minimizes the amount of credit exposure by investing cash that is not required for immediate operating needs in money market funds and marketable securities.</span></p>
CY2023Q3 us-gaap Asset Retirement Obligation
AssetRetirementObligation
0
CY2022Q3 us-gaap Asset Retirement Obligation
AssetRetirementObligation
0
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
31106000
CY2023Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
1029000
CY2023Q3 us-gaap Other Liabilities Fair Value Disclosure
OtherLiabilitiesFairValueDisclosure
1029000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
47461000
CY2023Q3 harp Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q4 harp Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
31105000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
31106000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
47464000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
47461000
CY2023Q3 harp Available For Sale Securities Accrued Interest Receivable
AvailableForSaleSecuritiesAccruedInterestReceivable
100000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3854000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15780000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
327000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8543000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3527000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7237000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1300000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1700000
CY2023Q3 harp Gain Loss On Sale And Disposition Of Assets
GainLossOnSaleAndDispositionOfAssets
0
harp Gain Loss On Sale And Disposition Of Assets
GainLossOnSaleAndDispositionOfAssets
400000
CY2023Q3 harp Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
8519000
CY2022Q4 harp Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
8569000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2677000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4760000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
444000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
896000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
57000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
136000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11697000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14361000
CY2023Q3 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
600000
us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
600000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
9400000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8857000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2974000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11530000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
14504000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
200000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
200000
us-gaap Variable Lease Cost
VariableLeaseCost
700000
us-gaap Variable Lease Cost
VariableLeaseCost
600000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1729000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4233000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4351000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4494000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2785000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
384000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17976000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3472000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
14504000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0932
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
918000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1780000
harp Extended Period Of Redemption Of Preferred Stock
ExtendedPeriodOfRedemptionOfPreferredStock
P2Y
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1802000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11640000
us-gaap Net Income Loss
NetIncomeLoss
-12079000
us-gaap Net Income Loss
NetIncomeLoss
-49312000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3947995
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3947995
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3306215
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3306215
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3807955
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3807955
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3299357
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3299357
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.52
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-14.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-14.95
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1466378
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
637737
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1466378
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
637737
CY2023Q4 us-gaap Class Of Warrant Or Right Reason For Issuing To Nonemployees
ClassOfWarrantOrRightReasonForIssuingToNonemployees
The October 2023 Cash Warrants and the October 2023 Pre-Funded Warrants issued in the Private Placement will provide that holder will not have the right to exercise any portion of its October 2023 Cash Warrants or October 2023 Pre-Funded Warrants if such holder, together with its affiliates, would beneficially own in excess of 4.99%, 9.99% or 19.9%, as applicable, of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise (the “Beneficial Ownership Limitation”). A holder may reset the Beneficial Ownership Limitation as to itself to a higher percentage (not to exceed 19.99%), effective 61 days after written notice to the Company.

Files In Submission

Name View Source Status
harp-20230930_def.xml Edgar Link unprocessable
0000950170-23-062125-index-headers.html Edgar Link pending
0000950170-23-062125-index.html Edgar Link pending
0000950170-23-062125.txt Edgar Link pending
0000950170-23-062125-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
harp-20230930.htm Edgar Link pending
harp-20230930.xsd Edgar Link pending
harp-ex31_1.htm Edgar Link pending
harp-ex31_2.htm Edgar Link pending
harp-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
harp-20230930_cal.xml Edgar Link unprocessable
harp-20230930_lab.xml Edgar Link unprocessable
harp-20230930_pre.xml Edgar Link unprocessable
harp-20230930_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending